GARDEN BIO-CHEM(300401)2025-01-13 11:46Financial Performance - The net profit attributable to shareholders is expected to be between 300 million and 350 million yuan, representing a year-on-year growth of 55.97% to 81.96%[3] - The net profit after deducting non-recurring gains and losses is projected to be between 250 million and 290 million yuan, indicating a year-on-year increase of 69.36% to 96.45%[3] - The overall operating revenue is expected to rise by around 13%, with total gross profit increasing by approximately 10%[5] Segment Performance - Revenue from the vitamin segment increased by approximately 55%, with gross profit rising by about 77%[5] Expenses and Gains - Marketing expenses for pharmaceutical products decreased by about 24% compared to the previous year[5] - The company recognized asset disposal gains of approximately 31 million yuan from the relocation of its Hangzhou subsidiary[5] - Non-recurring gains and losses are estimated to impact net profit by 50 million to 60 million yuan, mainly from subsidiary relocation asset disposal gains and government subsidies[6] Financial Reporting - The company has communicated with the accounting firm regarding the preliminary financial data, with no significant discrepancies reported[4] - The financial data provided is preliminary and will be detailed in the 2024 annual report, urging investors to exercise caution[7] - The performance forecast period is from January 1, 2024, to December 31, 2024[3]